BIOHEART-B
- Country
- 🇭🇰Hong Kong, China
- Ownership
- Public
- Established
- 2014-07-18
- Employees
- 54
- Market Cap
- -
- Website
- http://www.bio-heart.com
- Introduction
Shanghai Baixinan Biotechnology Co., Ltd. is a leading interventional cardiovascular device company in China. It is located in the Shanghai Zhangjiang Hi-Tech Park Medical Device Industrial Park. It focuses on two treatments, fully degradable stents (BRS) and renal nerve block (RDN), to address the unmet medical needs of Chinese patients with coronary and peripheral artery disease and hypertension.
The company has a leased area of about 6,500 square meters, has a clean workshop of about 40 million square meters and testing laboratories for all projects of related products, has established a quality management system that meets ISO13485/YY0287 standards, gathers professionals in machinery, materials, precision processing, clinical medicine, etc., and has a team of experienced talents in product design, quality control, clinical verification, and market development.
Clinical Trials
3
Trial Phases
1 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (3 trials with phase data)• Click on a phase to view related trials
A Registry Trial of The Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System
- Conditions
- Coronary Artery Disease
- First Posted Date
- 2019-11-26
- Last Posted Date
- 2021-02-26
- Target Recruit Count
- 785
- Registration Number
- NCT04179045
- Locations
- 🇨🇳
Beijing Anzhen Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳BeijingChao-YangHospital, Beijing, Beijing, China
🇨🇳Nanfang Hospital, Guangzhou, Guangdong, China
Bioheart Rapamycin Drug-Eluting Bioresorbable Coronary Stent System Clinical Study
- Conditions
- Coronary Artery DiseaseAntineoplastic Agents
- First Posted Date
- 2017-09-15
- Last Posted Date
- 2019-11-21
- Target Recruit Count
- 431
- Registration Number
- NCT03284255
- Locations
- 🇨🇳
Beijing Anzhen Hospital Capital Medical University, Beijing, Beijing, China
🇨🇳BeijingChao-YangHospital, Beijing, Beijing, China
🇨🇳Fuwai Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Galaxy Rapamycin Drug-Eluting Bioresorbable Coronary Stent System First-in-man Study
- Conditions
- Heart Diseases
- First Posted Date
- 2016-07-26
- Last Posted Date
- 2019-11-21
- Target Recruit Count
- 45
- Registration Number
- NCT02844270